Weight-loss drugs lower impulse to eat – and perhaps to exercise too
Popular weight-loss medications including Ozempic and Wegovy contain a drug that seems to decrease cravings for food and drugs – and now there’s evidence that it might make exercise less rewarding, to
Your employer may start covering weight-loss drugs soon
Still, more than a quarter of employers are considering adding coverage for GLP-1 drugs for weight loss in 2025 or 2026, according to a national survey conducted this year by Mercer, a human resources consulting firm.
Teens With Obesity Less Likely to Be Suicidal on Weight Loss Drugs: Study
Weight loss drugs like Ozempic were associated with a lower risk of suicidal thoughts in teens with obesity, a new study found.
WeightWatchers adds compounded version of Novo's obesity drug to weight-loss program
WeightWatchers said on Tuesday it would offer compounded form of Novo Nordisk's popular obesity drug Wegovy as part of its weight-management programs, sending its shares up 13% in early trading. Soaring demand for weight-loss drugs such as Wegovy and Eli Lilly's Zepbound,
In Good Health: The obesity rate is falling. What do weight loss drugs have to do with it?
As part of our series In Good Health, we discuss these new medications and the falling rate of obesity.
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
FDA will reconsider decision barring copycat versions of Lilly weight loss drug
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding pharmacies to continue selling their own versions.
Hims & Hers Stock Jumps as FDA Reconsiders Restrictions on Copycat Weight-Loss Drugs
Key Takeaways Hims & Hers shares gained Monday after the Food and Drug Administration said compounding pharmacies could continue to produce copycat weight-loss drugs while it reconsiders whether there is a shortage.
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.
Hims & Hers up 10% as FDA reconsiders taking Lilly weight loss drug off shortage list
Hims & Hers Health (NYSE:HIMS) is up ~10% in Monday morning trading following a recent lawsuit challenging the U.S. FDA's  decision to remove Eli Lilly's (NYSE:LLY) tirzepatide from a drug shortages list.
studyfinds9h
Study: Obese teens taking popular weight loss drugs less likely to consider suicide
Drugs like Ozempic and Wegovy may provide a surprising, life-saving benefit for the youngest patients taking these diabetes and weight loss medications.
Unemployed could be given weight loss jabs in trial to get them back to work
Health Secretary Wes Streeting said ‘widening waistbands’ were placing a burden on the NHS and leaving people out of work in ...
France won’t pay for weight loss drug Wegovy. What about other European countries?
France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on ...
Washingtonians share how they afford pricey weight loss medications
Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...
Medscape7d
Weight Loss After Anti-Obesity Medications Linked to Reduced Gout Risk
Achieving weight loss within a year of initiating orlistat can reduce the risk for both incident gout and recurrent gout ...